Comparing Evolus (NASDAQ:EOLS) and Aditxt (NASDAQ:ADTX)

Evolus (NASDAQ:EOLS) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares Evolus and Aditxt”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	1.64	-$51.64 million	($0.52)	-14.18
Aditxt	$14,336.00	0.05	-$41.71 million	($100,788.35)	-0.00

Aditxt has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.7% of Evolus shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Evolus and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Aditxt	-360,152.50%	-374.60%	-105.93%

Analyst Ratings

This is a summary of current recommendations for Evolus and Aditxt, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Aditxt	1	0	0	0	1.00

Evolus presently has a consensus target price of $14.50, suggesting a potential upside of 96.64%. Given Evolus’ stronger consensus rating and higher possible upside, research analysts clearly believe Evolus is more favorable than Aditxt.

Volatility and Risk

Evolus has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Summary

Evolus beats Aditxt on 11 of the 14 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.